<DOC>
	<DOCNO>NCT00062738</DOCNO>
	<brief_summary>The goal study evaluate effectiveness safety two antidepressant -- nortriptyline paroxetine , compare placebo patient Parkinson 's disease depression .</brief_summary>
	<brief_title>Treatment Depression Parkinson 's Disease Trial</brief_title>
	<detailed_description>Depression common neuropsychiatric disorder find patient Parkinson 's disease ( PD ) . It cause immense personal suffering associate increased disability caregiver burden . Despite adverse consequence depression patient PD , virtually empirical data guide clinical treatment . This study begin answer question treatment depression test SSRI ( selective serotonin reuptake inhibitor ) antidepressant , paroxetine , tricyclic antidepressant , nortriptyline , placebo placebo-controlled trial . A total 75 patient PD randomize three arm balance design .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Nortriptyline</mesh_term>
	<criteria>inclusion criterion : Parkinson 's disease without dementia . Depression . Males female . exclusion criterion : Psychosis Heart block</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Parkinson disease</keyword>
	<keyword>depression</keyword>
	<keyword>antidepressant</keyword>
	<keyword>nortriptyline</keyword>
	<keyword>paroxetine</keyword>
</DOC>